The human epidermal growth factor receptor 2 (HER2)-positive subtype, which accounts for 20–25% of all breast cancer cases [2,3], has gained substantial attention owing to its aggressive nature and resistance to treatment. This evidence concerns the gene ERBB2 and breast cancer.